- Spektus Pharma and GEBRO Holding have announced a global commercialization partnership for ActraFlex, a twice-daily extended-release tramadol/paracetamol formulation designed for pain management.
- ActraFlex combines Spektus’ patented AmyloFlex drug-delivery technology with GEBRO’s established Diliban brand, aiming to provide sustained drug release with convenient twice-daily dosing.
- Under the agreement, GEBRO will lead commercialization and supply across Europe and selected international markets, anchored by Spain. Spektus will oversee North and South America and selected Rest of World markets.
- The partnership combines GEBRO’s pain management expertise and commercial presence with Spektus’ drug-delivery platform and global partner network. Financial terms of the agreement were not disclosed.
Takeaways:
The Spektus–GEBRO partnership combines proprietary extended-release technology with an established pain-management brand to expand ActraFlex® across international markets. Twice-daily dosing could offer a convenience advantage over more frequent regimens, while GEBRO’s European presence and Spektus’ Americas network support market entry. Regulatory approvals, clinical differentiation and competition from existing analgesics will shape uptake.
Source: Spektus Pharma
